Partnering Strategy
Progress in-house assets through PoC and out-license development and commercial rights for large markets
(US, EU, Japan and China)
Open to range of models — global, regional, JV, spin-offs etc.
Commercialize across 'pharmerging' markets on our own or with partners
In-license differentiated clinic - ready assets for development and commercialization across RoW markets
Extend and execute early, registration trials across RoW geographies
Support CMC development and commercial supply mo, activities
Our Partners
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City (www.tgtxinc.com)
Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies
